← Back to screener

SpyGlass Pharma, Inc. SGP

Rank #1417 · Nasdaq · $1.1B market cap
Audited by Deloitte & Touche LLP, no going-concern flag in the latest filing.
Score
48.7
P/E
-37.0
P/B
-32.68
ROE
88.4%
Op. Margin
–%
Debt Ratio
-34%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -37.0x, P/B -32.68x. Ranks in the top 86% of the universe.

Profitability ★★★★★
Excellent

ROE 88.4%. Ranks in the top 4% of the universe.

Safety ★★★★★
Excellent

Debt ratio -34%. Ranks in the top 7% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Profitability is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2025–$-0.0B$-0.0B$-0.0B–-34

← See the full screener